explore -WSS

explore

author：entertainment 2025-10-02 14:38:36 - browse：44249

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Grad students accuse University of California of wage theft

WSS

People with substance use disorder deserve online privacy

Patients, doctors press FTC to beef up hospital merger scrutiny

Chamber of Commerce, DOJ clash in court over drug prices

Regeneron agrees to White House price limits on anti

Covid’s new normal has set in amid another rise in cases

Popular nasal decongestant doesn't actually relieve congestion

focus

explore

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Hospitals consider fixing cancer drug shortages on their own

Cancer drug shortages should be causing more outrage

Information blocking fines are now fair game in health care

Psychedelics group wrestles with new pharma identity

Chamber of Commerce, DOJ clash in court over drug prices

George Santos makes 1st court appearance after pleading not guilty to 13 counts

New Covid vaccine is recommended for everyone 6 months or older

New air purifier tech could be key to improving indoor air quality

FDA proposes changes to key medical devices approval pathway

hotspot

How medical schools plan to diversify without affirmative action

Akili changes sales model for its ADHD video game treatment

Will the IRA bring competition to the biologics market?

How medical schools plan to diversify without affirmative action

Food makers to regulators: Ultra

FDA weighs limits of animal data in assessing artificial wombs

focus

explore

focus

knowledge